drugset / Trial / NCT03610867
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349
Phase 1
Completed
64 enrolled
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd. · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of different doses of TG-2349 (Furaprevir capsule) in healthy Chinese volunteers.
Timeline
- Start
- 2017-04-27
- Primary completion
- 2017-08-31
- Completion
- 2017-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 100 mg | Oral |
| Subject | Furaprevir | Small molecule | 200 mg | Oral |
| Subject | Furaprevir | Small molecule | 400 mg | Oral |
| Subject | Furaprevir | Small molecule | 600 mg | Oral |
Indications
No indication recorded.